Tranexamic acid
General properties
Antihemorrhagic drugs, antifibrinolytic amino acids. fibrinolysis inhibitors.
Medicinal product Tranexamic Acid is indicated in patients with haemophilia for short-term administration (within 2-8 days) to reduce or prevent bleeding and to reduce the need for replacement therapy during and after tooth extraction.
– Acquired color vision impairment (this eliminates the possibility of measuring one endpoint, which should be monitored as an indicator of toxicity).
– Subarachnoid hemorrhage (tranexamic acid may cause cerebral edema and cerebral infarction).
– Active intravascular coagulation.
– Hypersensitivity to tranexamic acid or to the excipient.
Pharmaceutical characteristics
Clear colorless to slightly brown liquid.
Store in the original packaging at temperature not exceeding 25 °C. Keep out of reach of children.
